Dr. Clay Siegall founded Seattle Genetics in the year 1998. He is also the CEO of the company. Seattle Genetics deals in extensive research in modern medicine with its aim being to come up with new and more effective cancer treatment ways to replace the old ways which to a certain extent are normally ineffective. This company also focuses on coming up with intervention to diseases which in ages have been hard to cure.
Dr. Clay Siegall has decorated credentials in the field of genetics having graduated with a Doctorate in Philosophy from the University of Maryland and also holds a B.S in Zoology from the prestigious University of Maryland. Dr. Clay Siegall as the CEO of Seattle Genetics has led remarkable progress in the research especially in the field of pharmaceuticals. The company developed an antibody drug conjugate, ADCENTRIS (brentuximab vedotin) which was approved by the United States Foods and Drug Administration (FDA) in 2011. Seattle Genetics also has many other partners in the pharmaceutical industry such as Bayer, Pfizer, and Genentech among many others.
Dr. Clay Siegall motivation to venture in the field of medicinal research is to a great extent attributed to the illness of his relative. His relative who had cancer almost died due to the type of treatment that he was exposed to such as Chemotherapy, which was one of them. The treatment caused severe anemia to the victim. This motivated him to even think of other better modern ways of handling diseases such as cancer which are more effective and have fewer side effects.
Since getting a drug approved by FDA is an expensive process which is always long and tiring. Seattle Genetics usually uses other means of income to bring about its finances. This may include selling their drugs to health facilities. Before Clay founded Seattle Genetics, he worked in several other companies and institutions. Between 1991 and 1997, he worked with Bristol-Myers Squibb Pharmaceutical Institute. Clay also served at the National Cancer Organization from 1988 to 1991. Dr. Clay Siegall was also appointed by Ultragenyx Pharmaceutical Inc. as a member of the board of directors.